Measuring Chronic Pain Impact: Measurement Enhancement for Chronic Pain
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04426812 |
Recruitment Status :
Recruiting
First Posted : June 11, 2020
Last Update Posted : March 10, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Many complementary and integrative health approaches have been shown to be effective for chronic pain and included in guidelines. This evidence of effectiveness is built on hundreds of studies representing millions of research dollars, and the ability to analyze and better compare results across these studies is essential to obtain the full value of this investment. However, useful across-study comparisons which would allow better understanding and targeting of these interventions are hampered by at least two challenges: the lack of common outcome measures and the inability to meaningfully stratify or classify patients.
The first two Aims of this study each address one of these two challenges. The last Aim takes advantage of this study to further test the viability of MTurk as a data collection platform.
Specific Aim 1 addresses the lack of common outcome measures. This Aim is to develop and evaluate links or crosswalks between the PROMIS-29 and other common (legacy) measures used for chronic pain so that the results of studies using different measures can be compared. Our hypothesis here is that we will be able to create some sort of linkage between PROMIS and legacy measures that will allow for each pair estimates of one to be made from the other.
Specific Aim 2 addresses the inability to meaningfully stratify or subclassify chronic pain patients. This Aim is to evaluate and refine the chronic pain impact stratification scheme (ISS) proposes by the NIH Research Task Force on chronic low back pain, which is based on 9 PROMIS-29 items. Our hypothesis here is that the ISS can be refined so that it can identify subgroups of chronic pain patients with different levels of morbidity and different needs for treatment.
Specific Aim 3 addresses the potential for more efficient data collection using the MTurk platform. This Aim is to evaluate MTurk as a cost- and time-efficient method to collect quality data on individuals with chronic pain. Our hypothesis here is that we find that MTurk produces data of sufficient quality to be of use to future research projects.
Condition or disease | Intervention/treatment |
---|---|
Chronic Pain | Other: No intervention; just data collection |
While there is an extensive literature on the effectiveness of pharmaceutical and nonpharmacologic interventions for chronic low back pain (CLBP), it is challenging to synthesize the findings because of differences in the CLBP samples and in the outcome measures used. The NIH Research Task Force (RTF) on CLBP noted that these differences make it "difficult to compare epidemiologic data and studies of similar or competing interventions, replicate findings, pool data from multiple studies, resolve conflicting conclusions, develop multidisciplinary consensus, or even achieve consensus within a discipline regarding interpretation of findings." To this list we would add that these differences also prevent the use of the results to answer questions such as 'Which therapies work best? And for whom?' This project tackles two things that are needed to address these differences and allow for better cross-study comparisons: we will develop empirical links between different outcome measures to allow their expression in similar units (Aim 1), and we will refine the RTF's proposed stratification (subgrouping) of patients by the impact of their CLBP (Aim 2).
To address the first challenge, in Aim 1 this study will develop and evaluate crosswalks or links between components of the 29-item Patient-Reported Outcomes Measurement Information System (PROMIS®) short form (PROMIS-29) and common legacy measures used for chronic pain. The purpose of these crosswalks or links is to allow researchers who measured outcomes using one instrument to estimate what the outcome would be if it had been measured using the other instrument. In particular, we will create crosswalks/links for the two most commonly used instruments used to measure outcomes for CLBP: the Roland-Morris Disability Questionnaire (RMDQ) and the Oswestry Disability Index (ODI). In addition, depending on data availability and input from our Advisory Council we will create at least two other crosswalks/links between the PROMIS-29 and other legacy measures for CLBP (e.g., the Back Pain Functional Scale) or legacy measures for other types of chronic pain (e.g., the Neck Disability Index for chronic neck pain).
To address the second challenge, in Aim 2 we will evaluate and refine the chronic pain impact stratification scheme proposed by the NIH Research Task Force on chronic low back pain. The proposed scheme uses the Impact Stratification Score (ISS) which is calculated using 9 items from the PROMIS-29. This ISS was intended to identify and categorize patients with chronic pain into groups based on the severity of their condition so that treatment can be better targeted. We will first evaluate the ISS and its properties to determine whether they are stable across different samples and determine whether they can be improved. After we have finalized the components and calculation of the ISS, we will examine its effect on the impacts of chronic pain (e.g., health-related quality of life, healthcare utilization, worker productivity) to identify meaningful cut-points to use to stratify chronic pain patients into subgroups who exhibit different levels of chronic pain impact.
Three types of data will be used in the analyses to address Aims 1 and 2: data from existing datasets built during other studies, data collected from an anonymous national convenience sample using Amazon's Mechanical Turk (MTurk) crowdsourcing platform, and data from members of the probability-based nationally representative KnowledgePanel. Aim 3 will evaluate whether MTurk is a reliable, efficient method to collect data on individuals with chronic pain. One part of this evaluation will involve comparison of the results from MTurk to what was found using KnowledgePanel.
Study Type : | Observational |
Estimated Enrollment : | 3000 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Measuring Chronic Pain Impact |
Actual Study Start Date : | August 30, 2021 |
Estimated Primary Completion Date : | February 2023 |
Estimated Study Completion Date : | February 2023 |

Group/Cohort | Intervention/treatment |
---|---|
MTurk sample
Data collected from a sample of participants in an online convenience platform called MTurk who self-identify as having chronic pain.
|
Other: No intervention; just data collection
No intervention; just data collection |
KnowledgePanel
Data collected from a sample of panel members in an online representative panel called KnowledgePanel who self-identify as having chronic pain.
|
Other: No intervention; just data collection
No intervention; just data collection |
- Oswestry Disability Index (ODI) [ Time Frame: Baseline only ]Measure of function for those with chronic back pain; range 0-100; higher is worse
- Roland-Morris Disability Questionnaire (RMDQ) [ Time Frame: Baseline only ]Measure of function for those with chronic back pain; range 0-100; higher is worse
- Impact Stratification Score (ISS) [ Time Frame: Baseline only ]Measure of the level of impact chronic pain has on individual's lives; range 8-50; higher is worse
- PROMIS pain intensity [ Time Frame: Baseline only ]Measure of pain intensity; range 0-10; higher is worse
- PROMIS pain interference [ Time Frame: Baseline only ]Measure of the amount of interference pain causes in life; range 4-20; higher is worse
- PROMIS physical function [ Time Frame: Baseline only ]Measure of the impact of a condition on physical function; range 4-20; higher is worse
- Change in Impact Stratification Score (ISS) [ Time Frame: Baseline and 3 months ]Measure of the change in the level of impact chronic pain has on individual's lives; range -42 to +42; positive values are a worsening of impact

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
Sampling Method: | Non-Probability Sample |
Inclusion Criteria:
- adult
- self-described chronic pain
- member of one of the panels (MTurk or KnowledgePanel) we are using for data collection
Exclusion Criteria:
- unwillingness to participate

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04426812
Contact: Patricia M Herman, ND, PhD | 310-393-0411 ext 7129 | pherman@rand.org | |
Contact: Ron D Hays, PhD | 310.794.2294 | drhays@ucla.edu |
United States, California | |
Online recruitment only - nationwide | Recruiting |
Santa Monica, California, United States, 90407 | |
Contact: Patricia Herman, PhD 310-393-0411 ext 7129 |
Principal Investigator: | Patricia M Herman, ND, PhD | RAND |
Other Publications:
Responsible Party: | RAND |
ClinicalTrials.gov Identifier: | NCT04426812 |
Other Study ID Numbers: |
RHINO ID 2019-0651 1R01AT010402-01A1 ( U.S. NIH Grant/Contract ) |
First Posted: | June 11, 2020 Key Record Dates |
Last Update Posted: | March 10, 2022 |
Last Verified: | February 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Plan Description: | We have 3 types of data in this study. The first is using data from existing datasets gathered in other studies. We don't know whether we will be able to get permission to share those data. The second source is the MTurk sample. We hope to share those data and those of the third source KnowledgePanel. However, in each case we are limited by the regulations of those data collection platforms. |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Chronic Pain Pain Neurologic Manifestations |